Navepegritide
Brand Yuviwel · Code TransCon CNP
Ascendis Pharma's weekly CNP prodrug. US accelerated approval in February 2026 as Yuviwel; positive CHMP opinion in October 2026.
Navepegritide comes from Ascendis Pharma and sits in the Hormone pathways class on the board. Route: weekly injection. Use tracked here: Achondroplasia in children aged 2 and older with open growth plates. It stands at Approved on the board, with 1 news move logged; the latest is dated 24 Oct 2026.
- 05ApprovedHere now
- 04FiledApplication submitted to a regulator and under review.
- 03Phase 3Large confirmatory trials meant to support a filing.
- 02Phase 2Does it work at all, and at which dose? Hundreds of patients.
- 01Phase 1First doses in people. Safety, dose range, how the body handles it.
- Company
- Ascendis Pharma
- Mechanism
- Prodrug that releases active C-type natriuretic peptide continuously to counter overactive FGFR3 signalling at the growth plate
- Given as
- weekly injection
- Lead use on the board
- Achondroplasia in children aged 2 and older with open growth plates
- Moves logged
- 1latest 10 days ago
Navepegritide news moves
-
Navepegritide CHMP opinion moves weekly TransCon CNP toward an EU licence in achondroplasia
The EMA committee recommended Ascendis Pharma's weekly C-type natriuretic peptide prodrug for children with achondroplasia and open growth plates. The pivotal trial showed 1.49 cm more growth per year than placebo, and the Commission decision is due in the fourth quarter.
Other hormone pathways molecules on the board, with their current stage.